Results 71 to 80 of about 1,300 (156)

The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis

Indian Heart Journal
Background: Evaluate the effect of mavacamten on echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy (HCM).
Zina Otmani, Noura Abdrabou, Hazem Ayman Elsayed, Mazen Negmeldin Aly Yassin, Mohamed Abouzid, Mahmoud Diaa Hindawi, Ayman K. Awad   +6 more
doaj   +1 more source

Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The clinical benefits of mavacamten in patients with obstructive hypertrophic cardiomyopathy previously treated with advanced therapies are not established.
Daniele Massera, Elizabeth Adlestein, Sumar Frejat, Woon Y. Wu, Maria C. Reuter, Yuhe Xia, Isabel C. Alvarez, Mark V. Sherrid   +7 more
doaj   +1 more source

Efficacy and safety of Mavacamten for symptomatic Hypertrophic cardiomyopathy – an updated Meta-Analysis of randomized controlled trials

International Journal of Cardiology: Heart & Vasculature
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder with risk of sudden cardiac death (SCD) in children and adolescents. Mavacamten, also referred to as MYK-461, a myosin inhibitor of cardiac myocytes is studied in symptomatic HCM.
Irfan Ullah, Syeda Tayyaba Rehan, Zayeema Khan, Syed Hasan Shuja, Muhammad Hamza Shuja, Muhammad Irfan, Karthik Gonuguntla, M Chadi Alraies, Pratik Aggarwal, Sameer Raina, Yasar Sattar, Muhammad Sohaib Asghar   +11 more
doaj   +1 more source

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life.
Bryton J. Davis, Hailey Volk, Olives Nguyen, Daniel Kamna, Hongya Chen, Roberto Barriales‐Villa, Pablo Garcia‐Pavia, Iacopo Olivotto, Anjali T. Owens, Caroline J. Coats, Theodore P. Abraham, Scott D. Solomon, Martin S. Maron, Ahmad Masri   +13 more
doaj   +1 more source

Advancements in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Comprehensive Review

Journal of Cardiovascular Development and Disease
Hypertrophic cardiomyopathy (HCM) is characterized by excessive growth of myocardial tissue, most commonly due to genetic mutations in sarcomere proteins.
Randeep Gill, Arsalan Siddiqui, Brianna Yee, Michael V. DiCaro, Nazanin Houshmand, Tahir Tak   +5 more
doaj   +1 more source

Recent Advances in Novel Modulators for Cardiac Myosin Disorders

Pharmaceutical Fronts
In advanced stages of heart disease, most cases are characterized by heart failure, where the heart's systolic and diastolic functions are weakened, and then it cannot meet the body's normal oxygen demands.
Hancheng Wang, Mengfei Wang, Bo Han, Qiushi Chen, Qingwei Zhang   +4 more
doaj   +1 more source

Mavacamten for hypertrophic cardiomyopathy: effectiveness and value [PDF]

Journal of Managed Care & Specialty Pharmacy, 2022
Molly Beinfeld, Jason H Wasfy, Surrey Walton, Jyotirmoy Sarker, Emily Nhan, David M Rind, Steven D Pearson   +6 more
openaire   +1 more source

Myosin folding boosts solubility in cardiac muscle sarcomeres

JCI Insight
The polymerization of myosin molecules into thick filaments in muscle sarcomeres is essential for cardiac contractility, with the attenuation of interactions between the heads of myosin molecules within the filaments being proposed to result in ...
Colleen M. Kelly, Jody L. Martin, Michael J. Previs   +2 more
doaj   +1 more source

Mavacamten toxicity, hepatic dysfunction, and rifampicin: cause or coincidence? [PDF]

Eur Heart J Case Rep
Mapelli M, Costantino S, Maragna R.
europepmc   +1 more source

Mavacamten maintenance dose determination

\(\bf Aims\) Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction. This study evaluates real-world experience with mavacamten, focusing on maintenance dose determination to optimise individual therapy and enhance
Scholtz, Smita (PD Dr. med.), Coppée, Cédric (Dr. med.), Mohemed, Kawa (Dr. med.), Potratz, Max (Dr. med.), Sequeira, Vasco (Dr. rer. nat.), Rudolph, Volker (PD Dr. med.), Scholtz, Werner (Dr. med.), Reil, Jan-Christian (Dr. med.)   +7 more
openaire   +1 more source